IDT Biologika
Dedicated to Contract Development and Manufacturing of
Viral Vaccines, Viral Vectors and Biologics

Learn how IDT Biologika is responding to the COVID-19 outbreak

Contract Development and Manufacturing of Viral Vaccines, Viral Vectors and Biologics

IDT Biologika specializes in the contract development and manufacturing of Viral Vaccines, Gene and Immunotherapeutics as well as sterile liquids and lyophilized Biologics. We help biopharmaceutical and biotech companies as well as the US government as part of research consortia with the challenging and complex process of translating viral vaccines and biopharmaceuticals from the research lab through clinical development to large-scale commercial manufacturing inculding drug substance production, fill & finish, packaging and analytics. IDT Biologika provides fully integrated services for GMP compliant end-to-end services in BSL2 facilites meeting EMA, FDA and ANVISA standards.

We strive for strong, trusting and enduring customer partnerships. Our almost 100 year tradition in manufacturing vaccines and biopharmaceuticals motivates and obligates us to advance our clients’ products to prevent and treat diseases that impact the health of people worldwide.

Latest IDT News

Positive interim summary of strategic realignment at CPhl trade fair:

Tuesday, 5. November 2019

IDT Biologika expands portfolio of viral vaccines and biologics more info

IDT Biologika Awarded new Task Order to Manufacture Vaccines and Biologics for Infectious Diseases

Monday, 4. November 2019

IDT Biologika Awarded new Task Order in the Scope of 10-Year NIH Contract to Manufacture Vaccines and Biologics for Infectious Diseases more info

IDT Biologika inaugurates new multifunctional production facility for vaccines at BioPharmaPark area

Friday, 5. July 2019

New building for vaccine production enables even more flexible reaction to customer demands more info

Ceva completes acquisition

Wednesday, 3. July 2019

Ceva completes acquisition of IDT veterinary business assets, moving closer to its 2020 objective of 50:50 bio-pharma split more info

IDT Biologika to concentrate on human vaccines and pharmaceuticals

Wednesday, 5. June 2019

Divestment of animal health business unit enables focus on global growth market more info

@IDT Biologika

Friday, 29. May 2020

Once again, we are delighted to receive the CMO Leadership Awards in the three categories Capabilities, Compatibili… more info

Wednesday, 27. May 2020

RT @BMBF_Bund: Ein #Impfstoff ist nötig, um die #Corona #Pandemie unter Kontrolle zu bringen. BM @AnjaKarliczek hat nun mit drei wichtigen… more info

Wednesday, 20. May 2020

RT @ApothekeAdhoc: Marburger #Virologen wollen gemeinsam mit Kollegen noch im September beginnen, einen #Impfstoff gegen Sars-CoV-2 in erst… more info

Sunday, 17. May 2020

Our US-facility in #Rockville, MD offers custom, end to end solutions in viral (live and attenuated) processing for… more info

Sunday, 3. May 2020

As a #cmo of #vaccines and gene and immune therapy products, we also offer packaging services for clinical trial ma… more info

Friday, 17. April 2020

We take our social responsibility seriously and are now also producing #disinfectant to support people in our regio… more info

Wednesday, 1. April 2020

We are making every effort to protect our employees and to ensure the manufacturing of our clients‘ vital #vaccines… more info

Monday, 9. March 2020

IDT is recognized as a winner of three CMO Leadership Awards across the categories capabilities, compatibility and… more info

Friday, 14. February 2020

We are proud to be awarded a silver medal for #sustainability management once again! Following the silver medal in… more info